Hemlibra — United Healthcare
Hemophilia A (congenital factor VIII deficiency)
Initial criteria
- Diagnosis of hemophilia A
- Prescribed for the prevention of bleeding episodes (i.e., routine prophylaxis)
Reauthorization criteria
- Documentation of positive clinical response to Hemlibra therapy
Approval duration
12 months